Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 4, 2011

Primary Completion Date

January 9, 2014

Study Completion Date

January 9, 2014

Conditions
Recurrent Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
DIETARY_SUPPLEMENT

omega-3 fatty acid supplement

6 capsules per day (4.3 g)x 6 months

OTHER

Placebo

6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.

OTHER

Clinical assessments

All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.

OTHER

Assessment of therapy complications

Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

PROCEDURE

Magnetic Resonance Imaging

Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.

PROCEDURE

Correlative/special studies

Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
collaborator

Cancer and Leukemia Group B

NETWORK

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT01478477 - Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole | Biotech Hunter | Biotech Hunter